lilly glp-1 drug Novo, weight-loss drugs should be first option obesity treatments, European doctors say Prediction: Eli Lilly's Newest GLP-1

are the major companies operating in this market.

This drug, indicated for glycemic control in patients aged 10 years and above with type 2 diabetes, serves as an adjunct to diet and exercise

Initially developed to improve glycemic control, these agents are now recognized as important components of cardiovascular risk reduction strategies

Glucagon increases blood glucose levels, particularly during fasting, and facilitates the mobilization of energy reserves.Synthetic agonists like semaglutide and tirzepatide are stable peptides that specifically activate the receptors of these hormones, amplifying their beneficial effects on glycemic control and weight management